Becker's Healthcare October 23, 2024
Novo Nordisk has requested that the FDA prohibit compounding pharmacies from producing unapproved versions of its popular weight loss and diabetes drugs, Wegovy and Ozempic, CNBC reported Oct. 23.
The pharmaceutical company argues that the active ingredient in both drugs, semaglutide, is too complex for compounders to safely replicate. The move follows Novo Nordisk’s yearlong battle against clinics and pharmacies that manufacture and sell cheaper, unapproved versions of semaglutide amid shortages of the branded drugs in the...
Today's Sponsors
Today's Sponsor